PPIO-005 The Relationship Between Different Nutritional Pathways and Tumor Outcomes After Minimally Invasive Esophagectomy
Conditions: Esophageal Squamous Cell Carcinoma Sponsors: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 5, 2024 Category: Research Source Type: clinical trials
Real-world Experience of ICIs Plus Chemotherapy With or Without Radiotherapy for Advanced ESCC.
Conditions: Metastatic Esophageal Squamous Cell Carcinoma Interventions: Drug: Chemotherapy combined with immunotherapy; Radiation: radiotherapy Sponsors: Tianjin Medical University Cancer Institute and Hospital; Sichuan Cancer Hospital and Research Institute; Henan Cancer Hospital; Shanxi Province Cancer Hospital; Hunan Cancer Hospital Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 4, 2024 Category: Research Source Type: clinical trials
Local Therapy for Oligometastatic Esophageal Squamous Cell Cancer Patients Treated With PD-1 Inhibitor: a Prospective, Randomized, Phase III Clinical Trial.
Conditions: Esophageal Squamous Cell Carcinoma; Oligometastatic Disease; Radiotherapy Interventions: Combination Product: PD-1 inhibitor+/- chemotherapy combined with local therapy; Drug: PD-1 inhibitor+/- chemotherapy alone Sponsors: Fudan University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 4, 2024 Category: Research Source Type: clinical trials
A Clinical Study of Sintilimab as Adjuvant Therapy in Node-positive ESCC
Conditions: Esophageal Squamous Cell Carcinoma Interventions: Drug: sintilimab Sponsors: Zhejiang Cancer Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 4, 2024 Category: Research Source Type: clinical trials
Oral Microbiome is Associated With the Response to Chemoradiotherapy in Initial Inoperable Patients With Esophageal Squamous Cell Cancer
Conditions: Esophageal Squamous Cell Carcinoma; Chemoradiotherapy; Initial Inoperable Interventions: Other: regular chemoradiotherapy Sponsors: Anhui Provincial Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 4, 2024 Category: Research Source Type: clinical trials
Functional Imaging to Identify Radiosensitive Esophageal Cancer - a Biomarker Validation Study
Conditions: Esophagus Cancer Interventions: Diagnostic Test: Re Staging FDG-PET Sponsors: Sebastian Zschaeck; Helmholtz Zentrum Dresden Rossendorf, Dresden, Germany Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 4, 2024 Category: Research Source Type: clinical trials
Intermittent Oral-esophageal Tube Feeding in Delayed Dysphagia After Radiotherapy for Nasopharyngeal Carcinoma
Conditions: Nasopharyngeal Carcinoma; Dysphagia Interventions: Device: Intermittent Oral-esophageal Tube Feeding; Device: nasogastric tube feeding Sponsors: The First Affiliated Hospital of Zhengzhou University; Mianyang Central Hospital; Peking University Sixth Hospital Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 3, 2024 Category: Research Source Type: clinical trials
Consolidation of Toripalimab After Chemoradiotherapy in Elderly Esophageal Cancer (EC-CRT-007)
Conditions: Locally Advanced Esophageal Squamous Cell Carcinoma Interventions: Drug: S-1; Drug: Toripalimab; Radiation: Intensity-modulated radiotherapy Sponsors: Sun Yat-sen University; Nanfang Hospital, Southern Medical University; Zhujiang Hospital; Fifth Affiliated Hospital, Sun Yat-Sen University; Xiangya Hospital of Central South University; Wuhan University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 1, 2024 Category: Research Source Type: clinical trials
PD-1 Inhibitor Combined With Radiotherapy for Elderly ESCC
Conditions: Esophageal Squamous Cell Carcinoma Interventions: Drug: PD-1 inhibitor 200mg per three to four weeks, for one year Sponsors: Affiliated Hospital of Nantong University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 1, 2024 Category: Research Source Type: clinical trials
HAIC Combined Sintilimab for Liver Metastasis From Esophageal Squamous Cell Carcinoma
Conditions: Hepatic Arterial Infusion Chemotherapy; Liver Metastases; Esophageal Squamous Cell Carcinoma Interventions: Drug: HAIC combined with intravenous PD-1 Sponsors: Peking University Cancer Hospital& Institute; Innovent Biologics (Suzhou) Co. Ltd. Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 28, 2023 Category: Research Source Type: clinical trials
Serologic Response to Pneumococcal Vaccination Among Esophageal Cancer Patients With High Grade Lymphopenia After Chemoradiation
Conditions: Pneumococcal Vaccine; Esophageal Cancer; Lymphopenia; Chemoradiation Interventions: Biological: Pneumonia vaccine Sponsors: M.D. Anderson Cancer Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 25, 2023 Category: Research Source Type: clinical trials
Neoadjuvant Adebrelimab Plus Chemotherapy for Resectable ESCC: a Single Arm, Prospective Phase 2 Clinical Trial
Conditions: Esophageal Squamous Cell Carcinoma Interventions: Drug: Immunotherapy: Adebrelimab; Drug: chemotherapy: carboplatin plus nab-paclitaxel Sponsors: Shanghai Chest Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 20, 2023 Category: Research Source Type: clinical trials
Immunotherapy in Combination With Chemoradiotherapy in Unresectable Locally Advanced Esophageal Cancer
Conditions: Esophageal Squamous Cell Carcinoma; Unresectable Locally Advanced Esophageal Cancer Interventions: Drug: PD-1inhibitor; Drug: nab-paclitaxel + cisplatin; Radiation: Radiotherapy Sponsors: Shanghai Chest Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 18, 2023 Category: Research Source Type: clinical trials
Development and Validation of a Survival Prediction Model for Esophageal Cancer Patients After Esophagectomy
Conditions: Survivorship Interventions: Other: This was an observational study without any intervention Sponsors: Yongtao Han Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 14, 2023 Category: Research Source Type: clinical trials
Volatile Organic Compounds as Breath Biomarkers in Squamous Oesophageal Neoplasms
Conditions: Oesophageal Squamous Cell Carcinoma; Oesophageal Cancer Interventions: Other: Exhaled breath sampling Sponsors: Imperial College London; Imperial College Healthcare NHS Trust Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 13, 2023 Category: Research Source Type: clinical trials
